Previous 10 | Next 10 |
Lexicon Pharmaceuticals ( LXRX +4% ) is up on a 20x surge in volume on the heels of positive results from a Phase 1 multiple ascending-dose clinical trial evaluating neuropathic pain candidate LX9211 in healthy volunteers. More news on: Lexicon Pharmaceuticals, Inc., Healthcare stocks ...
Sage Therapeutics SAGE -62% after SAGE-217 flunks MDD study. More news on: Capricor Therapeutics, Inc., Axsome Therapeutics, Inc., Lexicon Pharmaceuticals, Inc., Stocks on the move, Read more ...
THE WOODLANDS, Texas, Dec. 05, 2019 (GLOBE NEWSWIRE) -- Lexicon Pharmaceuticals, Inc. (Nasdaq: LXRX), today announced positive topline data from the Phase 1 multiple ascending dose study of LX9211, a potent oral small molecule inhibitor of adaptor associated kinase 1 (AAK1), in developm...
Lexicon Pharmaceuticals ( LXRX +5.7% ) is up, albeit on below-average volume, on the heels of a safety review of the initial run-in cohort in a Phase 2 clinical trial, TELE-ABC , evaluating telotristat ethyl, combined with first-line chemo, for the treatment of patients with advanced bi...
THE WOODLANDS, Texas, Dec. 03, 2019 (GLOBE NEWSWIRE) -- Lexicon Pharmaceuticals, Inc. (Nasdaq: LXRX), announced today the completion of a safety review of the initial run-in cohort of the Tel otristat E thyl for A dvanced B iliary Tract C ancer, or TELE-ABC, study, which is a ...
Monday wasn't a good day on Wall Street, as major benchmarks started the final month of 2019 with across-the-board declines. The White House reignited trade disputes by taking away a previous exemption to steel tariffs for imports from Brazil and Argentina, and market watchers wondered what migh...
Gainers: Kodiak Sciences (NASDAQ: KOD ) +70% . More news on: Kodiak Sciences Inc., ASLAN Pharmaceuticals Limited, Cortexyme, Inc., Stocks on the move, Read more ...
Aqua Metals (NASDAQ: AQMS ) -41% after fire broke out at the plant. More news on: Aqua Metals, Inc., Lexicon Pharmaceuticals, Inc., Paringa Resources Limited, Stocks on the move, Read more ...
The FDA has denied Lexicon Pharmaceuticals' (NASDAQ: LXRX ) appeal of the CRL it received in March related to its marketing application for type 1 diabetes med sotagliflozin. Undeterred, it now plans to appeal the decision to the Center for Drug Evaluation and Research (CDER). More new...
THE WOODLANDS, Texas, Dec. 02, 2019 (GLOBE NEWSWIRE) -- Lexicon Pharmaceuticals, Inc. (Nasdaq: LXRX), today announced that the Office of New Drugs of the U.S. Food and Drug Administration (FDA) has reiterated the FDA's prior position and denied Lexicon's appeal of the Complete Response ...
News, Short Squeeze, Breakout and More Instantly...
Lexicon Pharmaceuticals Inc. Company Name:
LXRX Stock Symbol:
NASDAQ Market:
Lexicon Pharmaceuticals Inc. Website:
THE WOODLANDS, Texas, April 18, 2024 (GLOBE NEWSWIRE) -- Lexicon Pharmaceuticals, Inc. (NASDAQ:LXRX) today announced that senior company execut...
THE WOODLANDS, Texas, April 18, 2024 (GLOBE NEWSWIRE) -- Lexicon Pharmaceuticals, Inc. (Nasdaq: LXRX) today announced that senior company executives will be joined by leading physicians at the Lexicon 2024 Investor Day on April 22, 2024. The event will be held in New York City from 9:00 a...
THE WOODLANDS, Texas, April 03, 2024 (GLOBE NEWSWIRE) -- Lexicon Pharmaceuticals, Inc. (Nasdaq: LXRX) today announced Jeff Wade, Lexicon’s president and chief financial officer, Tom Garner, Lexicon’s senior vice president and chief commercial officer, and Craig Granowitz, M.D., ...